世界卫生组织II/III级胶质瘤分子状态:MRI形态学特征与表观扩散系数预测
回顾性分析290例未治疗WHO II/III级胶质瘤,由三名神经放射科医生盲法评估MRI形态特征及ADC值,构建两种模型预测IDH状态;模型A含钙化结果、模型B含囊肿形成,联合ADCmean与ADCNAWM比值及年龄,AUC分别为0.94和0.96,在49例测试样本中分类准确率分别为82%和86%。
要点
- ADCmean与正常表现白质ADC比值(ADCmean/ADCNAWM)联合年龄及形态特征可预测IDH状态。
- 模型A要求记录钙化结果,模型B记录囊肿形成,两者AUC分别为0.94和0.96。
- 测试样本中模型A分类准确率40/49(82%),模型B为42/49(86%)。
关键影像表现/征象
- 模型A要求记录钙化结果,模型B记录囊肿形成,两者均纳入ADCmean与ADCNAWM比值、年龄及形态学特征。
诊断标准与关键数值
- 模型A的AUC为0.94(95%CI:0.91,0.97),模型B的AUC为0.96(95%CI:0.93,0.98)。
- 测试样本49例(IDH野生型9例、IDH突变/1p19q完整21例、IDH突变/1p19q共缺失19例)中,模型A分类准确率40/49(82%;95%CI:71%,92%),模型B为42/49(86%;95%CI:76%,96%)。
- 观察者间一致性要求组内相关系数>0.8且Cohen κ>0.6的描述符才进入单变量分析,P<.05的预测变量进入多变量逻辑回归。
临床应用与阅片要点
- 可利用标准临床MRI序列测量的ADCmean/ADCNAWM比值、年龄及形态特征(钙化或囊肿形成)来预测WHO II/III级胶质瘤的IDH状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background A readily implemented MRI biomarker for glioma genotyping is currently lacking. Purpose To evaluate clinically available MRI parameters for predicting isocitrate dehydrogenase (IDH) status in patients with glioma. Materials and Methods In this retrospective study of patients studied from July 2008 to February 2019, untreated World Health Organization (WHO) grade II/III gliomas were analyzed by three neuroradiologists blinded to tissue results. Apparent diffusion coefficient (ADC) minimum (ADCmin) and mean (ADCmean) regions of interest were defined in tumor and normal appearing white matter (ADCNAWM). A visual rating of anatomic features (T1 weighted, T1 weighted with contrast enhancement, T2 weighted, and fluid-attenuated inversion recovery) was performed. Interobserver comparison (intraclass correlation coefficient and Cohen κ) was followed by nonparametric (Kruskal-Wallis analysis of variance) testing of associations between ADC metrics and glioma genotypes, including Bonferroni correction for multiple testing. Descriptors with sufficient concordance (intraclass correlation coefficient, >0.8; κ > 0.6) underwent univariable analysis. Predictive variables (P < .05) were entered into a multivariable logistic regression and tested in an additional test sample of patients with glioma. Results The study included 290 patients (median age, 40 years; interquartile range, 33-52 years; 169 male patients) with 82 IDH wild-type, 107 IDH mutant/1p19q intact, and 101 IDH mutant/1p19q codeleted gliomas. Two predictive models incorporating ADCmean-to-ADCNAWM ratio, age, and morphologic characteristics, with model A mandating calcification result and model B recording cyst formation, classified tumor type with areas under the receiver operating characteristic curve of 0.94 (95% confidence interval [CI]: 0.91, 0.97) and 0.96 (95% CI: 0.93, 0.98), respectively. In the test sample of 49 gliomas (nine IDH wild type, 21 IDH mutant/1p19q intact, and 19 IDH mutant/1p19q codeleted), the classification accuracy was 40 of 49 gliomas (82%; 95% CI: 71%, 92%) for model A and 42 of 49 gliomas (86%; 95% CI: 76%, 96%) for model B. Conclusion Two algorithms that incorporated apparent diffusion coefficient values, age, and tumor morphologic characteristics predicted isocitrate dehydrogenase status in World Health Organization grade II/III gliomas on the basis of standard clinical MRI sequences alone. © RSNA, 2020 Online supplemental material is available for this article.
引用
- Maynard J, Okuchi S, Wastling S, et al. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. Radiology. 2020. PMID: 32315266. doi:10.1148/radiol.2020191832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。